Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexanolone in Tinnitus
NCT05645432Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brexanolone in tinnitus, sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at Day 15. Started May 2023; status: completed.
02
Drugs
brexanolone
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT05645432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645432.